REGENXBIO Advances Gene Therapy Pipeline for Rare Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy RGNX?
Source: Newsfilter
- Clinical Trial Progress: REGENXBIO's RGX-202 for Duchenne muscular dystrophy shows promising Phase I/II results with an average 7.4-point improvement in functional scores over 18 months for four patients, with pivotal data expected in Q2 2026, potentially boosting stock performance.
- New Drug Development: The collaboration with AbbVie on sura-vec for wet AMD and diabetic retinopathy is set to initiate Phase IIb/III trials, with the first patient dosing expected in Q2 2026, which will trigger a $100 million milestone payment upon success.
- Financial Performance: As of December 31, 2025, REGENXBIO reported $240.9 million in cash and equivalents, a slight decrease from 2024, yet sufficient to fund operations into early 2027, indicating financial stability.
- Regulatory Interaction Plans: The company plans to engage with the FDA for a pre-BLA meeting in mid-2026 regarding RGX-121, despite facing clinical holds, and is committed to addressing FDA concerns to ensure future market access.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.630
Low
19.00
Averages
29.71
High
45.00
Current: 8.630
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased securities between February 9, 2022, and January 27, 2026, aiming to protect investors' legal rights.
- Investor Contact Information: The firm encourages investors who suffered losses during the specified period to contact partner Josh Wilson directly, providing multiple contact options to facilitate investor inquiries, demonstrating a commitment to client service.
- Class Action Deadline: Faruqi & Faruqi reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against REGENXBIO is April 14, 2026, emphasizing the importance of timely action.
- Securities Law Firm Background: As a leading national securities law firm, Faruqi & Faruqi's investigation indicates concerns over potential legal issues facing REGENXBIO, which could negatively impact the company's reputation and stock price.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to participate in the lawsuit.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, highlighting the critical importance of information transparency in securities markets.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
REGENXBIO Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds all investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that a class action lawsuit has been filed, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
- Safety Issues Revealed: The complaint alleges that despite REGENXBIO's claims of positive results for RGX-111 in clinical trials, the company was aware of serious safety concerns, including the potential for central nervous system tumors, leading to a decision in November 2023 to deprioritize the program.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 following the discovery of a case of intraventricular tumor in a trial participant, causing REGENXBIO's stock price to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
- Shareholder Action Guidance: Affected shareholders can submit their papers by April 14, 2026, to serve as lead plaintiffs in the class action, representing other shareholders without incurring any fees or expenses, highlighting Robbins LLP's commitment to shareholder rights.
See More
Class Action Alerts for PayPal and REGENXBIO Investors
- PayPal Lawsuit Overview: The class action against PayPal alleges that during the period from February 25, 2025, to February 2, 2026, management misrepresented the company's revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights that after the release of underwhelming financial results, PayPal announced the transition of CEO James Alexander Chriss, exacerbating market concerns about the company's future and undermining investor confidence.
- REGENXBIO Lawsuit Context: The class action involving REGENXBIO pertains to its gene therapy product RGX-111, with allegations that management disseminated false information from February 9, 2022, to January 27, 2026, leading to a 17.8% stock price decline after the FDA imposed a clinical hold on its trials.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of a brain tumor in a trial participant, raising serious concerns among investors regarding the product's safety and efficacy, which negatively impacted the company's market performance.
See More
Faruqi & Faruqi Investigates REGENXBIO for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential securities law violations by REGENXBIO, particularly concerning clinical trials for RGX-111 and RGX-121, with investors encouraged to apply as lead plaintiffs in a class action by April 14, 2026, to protect their rights.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapy RGX-111 due to a tumor case in a trial participant, causing the stock price to plummet by 17.9% to $11.01 per share, indicating serious market concerns over product safety.
- Investor Loss Notification: Faruq & Faruqi urges investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, to contact them to discuss potential legal options for seeking compensation in the class action lawsuit.
- Disclosure Failures: The complaint alleges that REGENXBIO and its executives failed to disclose significant adverse facts regarding the RGX-111 trial, which may have misled investors and negatively impacted the company's reputation and investor confidence.
See More
Reminder of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy trial, claiming positive data while concealing significant adverse facts about safety and efficacy, which ultimately led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Guidance: Investors are advised to choose legal counsel with proven success in securities class actions, as many firms merely act as intermediaries, and selecting experienced counsel is crucial for effectively protecting their rights.
See More
Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased securities between February 9, 2022, and January 27, 2026, aiming to protect investors' legal rights.
- Investor Contact Information: The firm encourages investors who suffered losses during the specified period to contact partner Josh Wilson directly, providing multiple contact options to facilitate investor inquiries, demonstrating a commitment to client service.
- Class Action Deadline: Faruqi & Faruqi reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against REGENXBIO is April 14, 2026, emphasizing the importance of timely action.
- Securities Law Firm Background: As a leading national securities law firm, Faruqi & Faruqi's investigation indicates concerns over potential legal issues facing REGENXBIO, which could negatively impact the company's reputation and stock price.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to participate in the lawsuit.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, highlighting the critical importance of information transparency in securities markets.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
REGENXBIO Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds all investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that a class action lawsuit has been filed, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
- Safety Issues Revealed: The complaint alleges that despite REGENXBIO's claims of positive results for RGX-111 in clinical trials, the company was aware of serious safety concerns, including the potential for central nervous system tumors, leading to a decision in November 2023 to deprioritize the program.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 following the discovery of a case of intraventricular tumor in a trial participant, causing REGENXBIO's stock price to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
- Shareholder Action Guidance: Affected shareholders can submit their papers by April 14, 2026, to serve as lead plaintiffs in the class action, representing other shareholders without incurring any fees or expenses, highlighting Robbins LLP's commitment to shareholder rights.
See More
Class Action Alerts for PayPal and REGENXBIO Investors
- PayPal Lawsuit Overview: The class action against PayPal alleges that during the period from February 25, 2025, to February 2, 2026, management misrepresented the company's revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights that after the release of underwhelming financial results, PayPal announced the transition of CEO James Alexander Chriss, exacerbating market concerns about the company's future and undermining investor confidence.
- REGENXBIO Lawsuit Context: The class action involving REGENXBIO pertains to its gene therapy product RGX-111, with allegations that management disseminated false information from February 9, 2022, to January 27, 2026, leading to a 17.8% stock price decline after the FDA imposed a clinical hold on its trials.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of a brain tumor in a trial participant, raising serious concerns among investors regarding the product's safety and efficacy, which negatively impacted the company's market performance.
See More
Faruqi & Faruqi Investigates REGENXBIO for Securities Violations
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential securities law violations by REGENXBIO, particularly concerning clinical trials for RGX-111 and RGX-121, with investors encouraged to apply as lead plaintiffs in a class action by April 14, 2026, to protect their rights.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapy RGX-111 due to a tumor case in a trial participant, causing the stock price to plummet by 17.9% to $11.01 per share, indicating serious market concerns over product safety.
- Investor Loss Notification: Faruq & Faruqi urges investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, to contact them to discuss potential legal options for seeking compensation in the class action lawsuit.
- Disclosure Failures: The complaint alleges that REGENXBIO and its executives failed to disclose significant adverse facts regarding the RGX-111 trial, which may have misled investors and negatively impacted the company's reputation and investor confidence.
See More
Reminder of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy trial, claiming positive data while concealing significant adverse facts about safety and efficacy, which ultimately led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Guidance: Investors are advised to choose legal counsel with proven success in securities class actions, as many firms merely act as intermediaries, and selecting experienced counsel is crucial for effectively protecting their rights.
See More
